Otsuka Pharmaceutical Co., Ltd. acquired Preclinical PD-1 Agonist Antibody Program of iBio, Inc. (NYSEAM:IBIO) on February 25, 2024. As a part of consideration, iBio will receive an upfront payment of $1.0 million in cash and $52.5 million in cash upon the achievement of certain pre-specified clinical development and commercial milestones.

Otsuka Pharmaceutical Co., Ltd. completed the acquisition of Preclinical PD-1 Agonist Antibody Program of iBio, Inc. (NYSEAM:IBIO) on February 25, 2024.